Cargando…

A case report of aggressive course of CD30+ primary cutaneous anaplastic large cell lymphoma

INTRODUCTION: CD30+ primary cutaneous anaplastic large cell lymphoma (PC-ALCL) is a rare T-cell neoplasm, and has been reported to present with an indolent behavior. The PC-ALCL with aggressive behavior has not been reported in the literature. PATIENT CONCERNS: We treated a patient with PC-ALCL that...

Descripción completa

Detalles Bibliográficos
Autores principales: Lyu, Wen-Tian, Song, Qi-Bin, Qiong, Wang, Liu, Jing, Yong, Ren, Yi, Feng-Tao, Han, Dong-liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8104231/
https://www.ncbi.nlm.nih.gov/pubmed/33950967
http://dx.doi.org/10.1097/MD.0000000000025770
_version_ 1783689450343104512
author Lyu, Wen-Tian
Song, Qi-Bin
Qiong, Wang
Liu, Jing
Yong, Ren
Yi, Feng-Tao
Han, Dong-liang
author_facet Lyu, Wen-Tian
Song, Qi-Bin
Qiong, Wang
Liu, Jing
Yong, Ren
Yi, Feng-Tao
Han, Dong-liang
author_sort Lyu, Wen-Tian
collection PubMed
description INTRODUCTION: CD30+ primary cutaneous anaplastic large cell lymphoma (PC-ALCL) is a rare T-cell neoplasm, and has been reported to present with an indolent behavior. The PC-ALCL with aggressive behavior has not been reported in the literature. PATIENT CONCERNS: We treated a patient with PC-ALCL that exhibited indolent behavior in the past 2 years and aggressive behavior within the last 3 months before presentation. DIAGNOSIS: Aggressive CD30+ primary cutaneous anaplastic large cell lymphoma. INTERVENTIONS: The radiotherapy regimen was individualized in terms of the target volume delineation and dose prescription, and the dose–response relationship was evaluated. OUTCOMES: The mean distance of microscopic infiltration was 14.1 mm in depth and 14.3 mm circumferentially. The lesion completely regressed after the delivery of 40 Gy in 20 fractions over 4 weeks. The tumor did not recur over the next year. CONCLUSION: An aggressive disease course is rare for indolent CD30+ PC-ALCL, which has similar histopathological characteristics as indolent PC-ALCL. The radiotherapy strategy should be individualized with curative intent.
format Online
Article
Text
id pubmed-8104231
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-81042312021-05-10 A case report of aggressive course of CD30+ primary cutaneous anaplastic large cell lymphoma Lyu, Wen-Tian Song, Qi-Bin Qiong, Wang Liu, Jing Yong, Ren Yi, Feng-Tao Han, Dong-liang Medicine (Baltimore) 5700 INTRODUCTION: CD30+ primary cutaneous anaplastic large cell lymphoma (PC-ALCL) is a rare T-cell neoplasm, and has been reported to present with an indolent behavior. The PC-ALCL with aggressive behavior has not been reported in the literature. PATIENT CONCERNS: We treated a patient with PC-ALCL that exhibited indolent behavior in the past 2 years and aggressive behavior within the last 3 months before presentation. DIAGNOSIS: Aggressive CD30+ primary cutaneous anaplastic large cell lymphoma. INTERVENTIONS: The radiotherapy regimen was individualized in terms of the target volume delineation and dose prescription, and the dose–response relationship was evaluated. OUTCOMES: The mean distance of microscopic infiltration was 14.1 mm in depth and 14.3 mm circumferentially. The lesion completely regressed after the delivery of 40 Gy in 20 fractions over 4 weeks. The tumor did not recur over the next year. CONCLUSION: An aggressive disease course is rare for indolent CD30+ PC-ALCL, which has similar histopathological characteristics as indolent PC-ALCL. The radiotherapy strategy should be individualized with curative intent. Lippincott Williams & Wilkins 2021-05-07 /pmc/articles/PMC8104231/ /pubmed/33950967 http://dx.doi.org/10.1097/MD.0000000000025770 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/)
spellingShingle 5700
Lyu, Wen-Tian
Song, Qi-Bin
Qiong, Wang
Liu, Jing
Yong, Ren
Yi, Feng-Tao
Han, Dong-liang
A case report of aggressive course of CD30+ primary cutaneous anaplastic large cell lymphoma
title A case report of aggressive course of CD30+ primary cutaneous anaplastic large cell lymphoma
title_full A case report of aggressive course of CD30+ primary cutaneous anaplastic large cell lymphoma
title_fullStr A case report of aggressive course of CD30+ primary cutaneous anaplastic large cell lymphoma
title_full_unstemmed A case report of aggressive course of CD30+ primary cutaneous anaplastic large cell lymphoma
title_short A case report of aggressive course of CD30+ primary cutaneous anaplastic large cell lymphoma
title_sort case report of aggressive course of cd30+ primary cutaneous anaplastic large cell lymphoma
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8104231/
https://www.ncbi.nlm.nih.gov/pubmed/33950967
http://dx.doi.org/10.1097/MD.0000000000025770
work_keys_str_mv AT lyuwentian acasereportofaggressivecourseofcd30primarycutaneousanaplasticlargecelllymphoma
AT songqibin acasereportofaggressivecourseofcd30primarycutaneousanaplasticlargecelllymphoma
AT qiongwang acasereportofaggressivecourseofcd30primarycutaneousanaplasticlargecelllymphoma
AT liujing acasereportofaggressivecourseofcd30primarycutaneousanaplasticlargecelllymphoma
AT yongren acasereportofaggressivecourseofcd30primarycutaneousanaplasticlargecelllymphoma
AT yifengtao acasereportofaggressivecourseofcd30primarycutaneousanaplasticlargecelllymphoma
AT handongliang acasereportofaggressivecourseofcd30primarycutaneousanaplasticlargecelllymphoma
AT lyuwentian casereportofaggressivecourseofcd30primarycutaneousanaplasticlargecelllymphoma
AT songqibin casereportofaggressivecourseofcd30primarycutaneousanaplasticlargecelllymphoma
AT qiongwang casereportofaggressivecourseofcd30primarycutaneousanaplasticlargecelllymphoma
AT liujing casereportofaggressivecourseofcd30primarycutaneousanaplasticlargecelllymphoma
AT yongren casereportofaggressivecourseofcd30primarycutaneousanaplasticlargecelllymphoma
AT yifengtao casereportofaggressivecourseofcd30primarycutaneousanaplasticlargecelllymphoma
AT handongliang casereportofaggressivecourseofcd30primarycutaneousanaplasticlargecelllymphoma